Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant (email | Twitter) and we will feature it...
Our readers who regularly check our website know that we kept up with the news online. But for everyone else, here's a roundup of the regulatory actions you may have missed.
Alexza Pharmaceuticals ($ALXA) has won a long-sought approval for an antipsychotic drug called Adasuve from the FDA. Wasting no time, the company plans to push the inhaled med onto the U.S. market early in the first quarter of 2013.
The FDA shot down the company's latest application because of manufacturing deficiencies related to the device used to take the inhaled antipsychotic drug, the company revealed last night.
Alexza Pharmaceuticals may be literally going for broke as it pursues approval of its inhaled fast-acting antipsychotic drug Adasuve. The company ($ALXA) announced that it will pursue significant,
Just days after eking out an FDA expert panel vote in favor of its inhaled antipsychotic Adasuve, Alexza Pharma ($ALXA) has brought in Lazard to investigate the possible sale of assets as it prepares
Alexza Pharma ($ALXA) just barely managed to clear one of the big hurdles that threatened to once again block its marathon effort at winning an FDA approval of the inhaled antipsychotic treatment
Investors appeared to get worried after FDA staffers cited worries about lung safety issues with Alexza Pharmaceuticals' ($ALXA) inhaled anti-agitation drug Adasuve. Shares of the developers stock
With the FDA blocking an approval for Alexza's ($ALXA) anti-agitation treatment Adasuve (AZ-004), the U.S. biotech has forged ahead with a European pact that brings a $10 million upfront payment with
Alexza Pharmaceuticals ($ALXA) says it has had a chance to sit down with the FDA to discuss its stalled application for AZ-004, an inhaled, fast-acting treatment for the management of schizophrenia